GlassScriptPhysician profile
Ravi Juluri
NPI 1457523151
$14,083.75
in general payments reported to CMS, 2019-2025
35 companies · $3,542 in 2025
The $3,542 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $227 · 2021: $777 · 2022: $2,757 · 2023: $2,932 · 2024: $2,862 · 2025: $3,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,320 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,319.63 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,530.28 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,618.47 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,331.62 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,115.61 | 2019-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $620.23 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $598.02 | 2019-2025 | Tremfya |
| Gilead Sciences, INC. | $467.74 | 2019-2025 | |
| Celgene Corporation | $417.64 | 2022-2024 | Zeposia |
| Genzyme Corporation | $415.52 | 2022-2025 | |
| Madrigal Pharmaceuticals | $305.70 | 2025 | Rezdiffra |
| Qol Medical, LLC | $282.57 | 2022-2025 | Sucraid |
| Ardelyx, INC. | $269.90 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $264.33 | 2020-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $236.97 | 2021-2022 | |
| Lilly USA, LLC | $213.75 | 2024-2025 | Omvoh |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $157.14 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $142.48 | 2024-2025 | Vegzelma |
| Redhill Biopharma INC. | $138.19 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $137.43 | 2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $135.67 | 2021-2023 | |
| Pfizer INC. | $134.15 | 2019-2025 | |
| Organon LLC | $72.78 | 2022-2024 | Renflexis |
| Ferring Pharmaceuticals INC. | $71.04 | 2019-2025 | Rebyota |
| Daiichi Sankyo INC. | $65.77 | 2021-2022 | |
| Ucb, INC. | $53.00 | 2019-2024 | Cimzia |
| Pharmacosmos Therapeutics INC. | $52.12 | 2024-2025 | Monoferric |
| Merck Sharp & Dohme LLC | $45.23 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $44.05 | 2021-2023 | Ocaliva |
| Fresenius Kabi USA, LLC | $32.21 | 2023 | Idacio |
| Boston Scientific Corporation | $24.39 | 2019 | |
| Novo Nordisk INC | $23.78 | 2025 | Wegovy |
| Evoke Pharma, INC. | $21.11 | 2023 | Gimoti |
| Tersera Therapeutics LLC | $18.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2023 | Cyltezo |
| Shire North American Group INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Juluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.